Telix Pharmaceuticals | TLX - 债务利息支出



金融业
股票价格
AUD
资产
AUD 1.36B
现金及等价物
AUD 141.87M
销售成本
AUD 245.71M
流动资产
AUD 488.02M
流动负债
AUD 242.34M
债务
AUD 467.11M
EBIT
AUD 46.36M
EBITDA
AUD 76.49M
EPS每股收益
AUD 0.1
股本和储备
AUD 408.17M
销售毛利
AUD 260.35M
债务利息支出
AUD 19.39M
利息收入
AUD 1.37M
贷款资金
AUD 564.44M
市值
AUD 5.02B
净收入
AUD 38.33M
营业费用
AUD 430.99M
营业利润
AUD 46.36M
普通股股本
AUD 339.79M
PE价格收益
223.36
税前利润
AUD 76.73M
销售收入
AUD 477.35M
销售和管理费用
AUD 107.02M
股票
AUD 37.08M
贸易债权人
AUD 168.97M
应收帐款人
AUD 170.39M


债务利息支出 更改 日
Cochlear AUD 6.3M 3.65M 2025-12
CSL USD 215M 111M 2025-12
Integral Diagnostics AUD 5.34M 6.08M 2024-06
Mayne Pharma AUD 1.2M 50K 2024-06
Medical Developments International AUD 18K 3K 2025-06
Mesoblast USD 11.29M 461K 2025-12
Neuren Pharmaceuticals AUD 0 0 2024-06
Paradigm Biopharmaceuticals AUD 1000 3K 2025-06
Polynovo AUD 506K 130K 2025-06
PYC Therapeutics AUD 17K 11K 2025-06
Ramsay Health Care AUD 300.6M 15.5M 2025-12
ResMed USD 775K 886K 2024-12
Sonic Healthcare AUD 86.91M 43.94M 2024-12